Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Will TH1902 extend life? Key question

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Jul 27, 2022 4:30pm

97 Views

Post# 34854981

RE:Will TH1902 extend life? Key question

PFS and parameters like that means nothing on a single patient.

TH1902 wrote: I'm no cancer doc, just trying to learn, seems to me that one patient on TH1902 had a 33 wk course with no worsening...or am I wrong on this???

Below is what Trodelvy has done:

Seems to me, TH1902 has potential but we NEED MORE DATA imo...

Source : https://www.google.com/search?q=trodelvy+life+extension+cancer&rlz=1C1CHBF_enCA879CA879&oq=trodelvy+life+extension+cancer&aqs=chrome..69i57j33i160l4.9672j0j15&sourceid=chrome&ie=UTF-8

The researchers found that people taking Trodelvy had an average progression-free survival time—a period without worsening of disease—of 4.6 months compared with 2.3 months for those on chemotherapy. The median overall survival time was 12.4 months versus 6.7 months, respectively.Oct 21, 2021